204 related articles for article (PubMed ID: 20197480)
1. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
[TBL] [Abstract][Full Text] [Related]
2. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
Panebianco V; Sciarra A; De Berardinis E; Busetto GM; Lisi D; Buonocore V; Gentile V; Di Silverio F; Passariello R
Anticancer Res; 2011 Apr; 31(4):1399-405. PubMed ID: 21508392
[TBL] [Abstract][Full Text] [Related]
3. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
Sciarra A; Panebianco V; Salciccia S; Osimani M; Lisi D; Ciccariello M; Passariello R; Di Silverio F; Gentile V
Eur Urol; 2008 Sep; 54(3):589-600. PubMed ID: 18226441
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
5. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
6. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
[TBL] [Abstract][Full Text] [Related]
7. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
[TBL] [Abstract][Full Text] [Related]
8. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.
Parivar F; Hricak H; Shinohara K; Kurhanewicz J; Vigneron DB; Nelson SJ; Carroll PR
Urology; 1996 Oct; 48(4):594-9. PubMed ID: 8886066
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
11. Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci.
Sciarra A; Panebianco V; Salciccia S; Gentilucci A; Alfarone A; Dimare L; Lisi D; Catturino S; Di Pierro G; Von Heland M; Ciccariello M; Passariello R; Gentile V
Urol Oncol; 2011; 29(6):634-40. PubMed ID: 19914107
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results.
Bhatia C; Phongkitkarun S; Booranapitaksonti D; Kochakarn W; Chaleumsanyakorn P
J Med Assoc Thai; 2007 Jul; 90(7):1391-9. PubMed ID: 17710982
[TBL] [Abstract][Full Text] [Related]
13. Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).
Panebianco V; Sciarra A; Ciccariello M; Lisi D; Bernardo S; Cattarino S; Gentile V; Passariello R
Radiol Med; 2010 Dec; 115(8):1314-29. PubMed ID: 20852963
[TBL] [Abstract][Full Text] [Related]
14. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
Lawrentschuk N; Fleshner N
BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
[TBL] [Abstract][Full Text] [Related]
15. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
16. Morphologic, functional, and metabolic magnetic resonance imaging-guided prostate biopsy in a patient with prior negative transrectal ultrasound-guided biopsies and persistently elevated prostate-specific antigen levels.
Lichy MP; Anastasiadis AG; Aschoff P; Sotlar K; Eschmann SM; Pfannenberg C; Stenzl A; Claussen CD; Schlemmer HP
Urology; 2007 Jun; 69(6):1208.e5-8. PubMed ID: 17572221
[TBL] [Abstract][Full Text] [Related]
17. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
Villers A; Puech P; Mouton D; Leroy X; Ballereau C; Lemaitre L
J Urol; 2006 Dec; 176(6 Pt 1):2432-7. PubMed ID: 17085122
[TBL] [Abstract][Full Text] [Related]
19. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
20. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.
Anastasiadis AG; Lichy MP; Nagele U; Kuczyk MA; Merseburger AS; Hennenlotter J; Corvin S; Sievert KD; Claussen CD; Stenzl A; Schlemmer HP
Eur Urol; 2006 Oct; 50(4):738-48; discussion 748-9. PubMed ID: 16630688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
